ym 872 has been researched along with lomerizine in 4 studies
| Studies (ym 872) | Trials (ym 872) | Recent Studies (post-2010) (ym 872) | Studies (lomerizine) | Trials (lomerizine) | Recent Studies (post-2010) (lomerizine) |
|---|---|---|---|---|---|
| 41 | 0 | 5 | 100 | 3 | 29 |
| Protein | Taxonomy | ym 872 (IC50) | lomerizine (IC50) |
|---|---|---|---|
| Delta-type opioid receptor | Mus musculus (house mouse) | 2.43 | |
| Voltage-dependent L-type calcium channel subunit beta-1 | Rattus norvegicus (Norway rat) | 0.09 | |
| Voltage-dependent calcium channel subunit alpha-2/delta-1 | Rattus norvegicus (Norway rat) | 0.09 | |
| Voltage-dependent N-type calcium channel subunit alpha-1B | Homo sapiens (human) | 2.43 | |
| Voltage-dependent N-type calcium channel subunit alpha-1B | Rattus norvegicus (Norway rat) | 0.09 | |
| Prostaglandin D2 receptor 2 | Homo sapiens (human) | 0.09 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartlett, CA; Chiha, W; Fitzgerald, M; Giacci, MK; Harvey, AR; Hodgetts, SI; O'Hare Doig, RL; Smith, NM; Yates, NJ | 1 |
| Fehily, B; Fitzgerald, M; Gavriel, N; Giacci, MK; Gough, AH; Gray, CGG; Milbourn, HR; Toomey, LM | 1 |
| Bartlett, CA; Fitzgerald, M; Gopalasingam, G; Majimbi, M; Rodger, J; Toomey, LM | 1 |
| Bartlett, CA; Fitzgerald, M; Gavriel, N; Gopalasingam, G; Majimbi, M; McGonigle, T; Rodger, J; Toomey, LM | 1 |
1 review(s) available for ym 872 and lomerizine
| Article | Year |
|---|---|
Limiting oxidative stress following neurotrauma with a combination of ion channel inhibitors.
Topics: Animals; Calcium; Central Nervous System; Humans; Imidazoles; Myelin Sheath; Nerve Degeneration; Oxidative Stress; Piperazines; Quinoxalines; Reactive Oxygen Species | 2017 |
3 other study(ies) available for ym 872 and lomerizine
| Article | Year |
|---|---|
Specific ion channels contribute to key elements of pathology during secondary degeneration following neurotrauma.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Disease Models, Animal; Female; Imidazoles; Macrophages; Microglia; Nerve Degeneration; Nystagmus, Optokinetic; Optic Nerve Injuries; Oxidative Stress; Piperazines; Purinergic P2X Receptor Antagonists; Quinoxalines; Random Allocation; Ranvier's Nodes; Rats; Receptors, AMPA; Receptors, Purinergic P2X7 | 2017 |
Comparison of ion channel inhibitor combinations for limiting secondary degeneration following partial optic nerve transection.
Topics: Animals; Calcium Channel Blockers; Calcium-Binding Proteins; Cell Adhesion Molecules, Neuronal; Disease Models, Animal; Drug Delivery Systems; Drug Therapy, Combination; Ectodysplasins; Female; Imidazoles; Ion Channels; Macrophages; Microfilament Proteins; Microglia; Nerve Degeneration; Nystagmus, Optokinetic; Oligodendrocyte Transcription Factor 2; Optic Nerve Injuries; Piperazines; Quinoxalines; Rats; Receptor, Platelet-Derived Growth Factor alpha; Rosaniline Dyes; Tubulin | 2019 |
Comparing modes of delivery of a combination of ion channel inhibitors for limiting secondary degeneration following partial optic nerve transection.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Drug Therapy, Combination; Female; Imidazoles; Myelin Sheath; Nerve Degeneration; Optic Nerve; Optic Nerve Injuries; Piperazines; Quinoxalines; Rats; Receptors, AMPA; Receptors, Purinergic P2X7; Rosaniline Dyes | 2019 |